-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $273

Benzinga·02/12/2026 14:41:12
Listen to the news
Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $240 to $273.